|
IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms. The London-based investor in the science and technology sector said Enterprise Therapeutics Ltd had share the results of a phase-two trial of inhaled EDT001, its lead drug candidate for cystic fibrosis. EDT001 was tested ‘in the 10% of people with cystic fibrosis with the highest unmet medical need and achieved its primary efficacy outcome’, IP Group noted. The drug led to ‘clinically meaningful improvement in lung function over a 28-day period compared to placebo’, and adverse effects ‘were consistent with those expected in this patient population’. Enterprise plans to progress the drug to longer-duration phase 2b trials, combining it with cystic fibrosis transmembrane modulator therapies. IP Group Chief Executive Greg Smith commented: ‘This is a highly encouraging clinical milestone for Enterprise Therapeutics and a strong validation of its differentiated approach to cystic fibrosis. Demonstrating a clinically meaningful improvement in lung function in a population with significant unmet need highlights the potential of ETD001. For IP Group, this represents another example of our model providing investors with access to differentiated deep science opportunities.’ IP Group shares fell 1.2% to 65.22p on Tuesday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
